Drug intelligence / Profile preview

OCUL101

Development stage: Phase 3
Lead developer: Shenzhen Oculgen Biomedical Technology
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Ophthalmic

Overview

OCUL101 is a recombinant humanized bispecific monoclonal antibody developed by Shenzhen Okejian Biopharmaceutical Technology for the treatment of retinal diseases. It simultaneously targets vascular endothelial growth factor (VEGF) and complement component 5 (C5). This dual-action mechanism is intended to treat neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) by inhibiting angiogenesis and vascular leakage, while also addressing geographic atrophy (GA) by modulating the complement-mediated inflammatory response. OCUL101 is administered via intravitreal injection and is currently undergoing Phase 1/2 clinical evaluation to assess its safety, tolerability, and preliminary efficacy in patients with these vision-threatening conditions.

Other names: bispecific anti-VEGF and anti-complement antibodyanti-VEGF/C5 bispecific antibodyOCUL-101OCUL101OCUL 101

Targets

VEGFA (Vascular endothelial growth factor A)C5

Beyond the preview

Go deeper on OCUL101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OCUL101.

Explore the full profile